Fig. 2.

hAMSCs alleviated aGVHD in NPG mice. (A) A schematic diagram illustrating administration schedule of hAMSCs in aGVHD mouse models. (B) Changes of body weight in different groups (n = 10). (C) aGVHD clinical score (based on weight loss, hunched posture, ruffled fur, skin lesions, reduced mobility and diarrhea) in different groups (n = 10). (D) Survival among different groups (n = 10). (E) Representative microscopic pictures of H&E staining (400 ×) and histology score (based on the tissues structure destruction and lymphocyte infiltration) (n = 4). (F) Representative microscopic pictures of immunohistochemistry (400 ×) and the proportion of CD45 positive area (n = 4). Values were presented as mean ± SD